| Mantle cell lymphoma

Tecartus vs Jaypirca

Side-by-side clinical, coverage, and cost comparison for mantle cell lymphoma.

Deep comparison between: Tecartus vs Jaypirca with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsJaypirca has a higher rate of injection site reactions vs Tecartus based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Jaypirca but not Tecartus, including UnitedHealthcare

Category

Tecartus

Jaypirca

At A Glance

RouteIV infusion

FrequencySingle infusion

ClassCD19-directed CAR-T cell therapy

RouteOral

FrequencyOnce daily

ClassBTK inhibitor

Indications

Mantle cell lymphoma
Precursor B-cell lymphoblastic leukemia

Mantle cell lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Dosing

Mantle cell lymphoma Single IV infusion at 2 x 10^6 CAR-positive viable T cells/kg (max 2 x 10^8 cells) following lymphodepleting chemotherapy with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on each of the fifth, fourth, and third day before infusion.

Precursor B-cell lymphoblastic leukemia Single IV infusion at 1 x 10^6 CAR-positive viable T cells/kg (max 1 x 10^8 cells) following lymphodepleting chemotherapy with fludarabine 25 mg/m2 IV on days -4, -3, and -2 and cyclophosphamide 900 mg/m2 IV on day -2 before infusion.

Mantle cell lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.

Contraindications

—

Drug Interactions

26View drug interactions

704View drug interactions

Adverse Reactions

Most common (>=20%) - MCL CRS, fever, encephalopathy, hypotension, infection with pathogen unspecified, viral infections, fatigue, tachycardias, chills, hypoxia, tremor, cough, musculoskeletal pain, nausea, edema, headache, constipation, diarrhea, decreased appetite, dyspnea, rash, insomnia, pleural effusion, aphasia, motor dysfunction

Most common (>=20%) - ALL fever, CRS, hypotension, encephalopathy, tachycardia, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, vomiting

Serious encephalopathy, fever, infection with pathogen unspecified, CRS, hypoxia, aphasia, renal insufficiency, pleural effusion, respiratory failure, bacterial infections, dyspnea, fatigue, arrhythmia, tachycardia, viral infections

Postmarketing infusion related reaction; T cell malignancies (identified with BCMA- or CD19-directed genetically modified autologous T cell immunotherapies)

Most common (>=30%) Decreased neutrophil count, decreased hemoglobin, decreased leukocytes, fatigue, decreased platelets, decreased lymphocyte count, calcium decreased

Serious Pneumonia, COVID-19, sepsis, febrile neutropenia, hemorrhage, pleural effusion

Pharmacology

CD19-directed genetically modified autologous T cell immunotherapy; binding of anti-CD19 CAR T cells to CD19-expressing target cells activates CD28 and CD3-zeta co-stimulatory signaling cascades leading to T cell activation, proliferation, acquisition of effector functions, secretion of inflammatory cytokines and chemokines, and killing of CD19-expressing cancer and normal B cells.

Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK, a signaling protein of the B-cell antigen receptor and cytokine receptor pathways; it binds wild-type BTK and BTK harboring C481 mutations to inhibit BTK kinase activity and suppress malignant B-cell proliferation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Tecartus